Coronary artery disease in South Asians: what is known and what remains to be known
===================================================================================

Among cardiovascular diseases, coronary artery disease (CAD) is the leading cause of death in the United States (US), and certain populations, such as South Asians, African Americans, and Hispanics, carry a disproportionately larger burden of CAD ([@b74-vhrm-4-0953]; [@b60-vhrm-4-0953]; [@b38-vhrm-4-0953]). The mortality rates from CAD in South Asians are reported to be two to three times higher than those for Caucasians, irrespective of gender, religion, social class, dietary practices or country of residence ([@b20-vhrm-4-0953]; [@b38-vhrm-4-0953]). This higher prevalence is seen in South Asian immigrants (SAIs) in the US as well as in those living in India, and rates are similar among vegetarians and nonvegetarians ([@b20-vhrm-4-0953], [@b19-vhrm-4-0953]; [@b51-vhrm-4-0953]; [@b29-vhrm-4-0953]; [@b38-vhrm-4-0953]). South Asian Indian women in California have the highest death rate from CAD in the United States, higher than Caucasians, Blacks, Hispanics, and Native Americans ([@b41-vhrm-4-0953]). Specifically, 33% of all deaths among Indian women are due to CAD compared with 11% among Japanese, 16% among Chinese, and 20% among Hispanics, Blacks, and Caucasians. In California, SAIs have the highest rate of hospitalization for CAD, and Chinese have the lowest rate. The high rates of CAD among SAIs are not limited to the US and appear to be part of a global phenomenon ([@b10-vhrm-4-0953]). Further, CAD risk factors are present in South Asians at a younger age compared to other populations, resulting in CAD at a younger age than in other populations ([@b38-vhrm-4-0953]). The reasons for early development of CAD risk factors at a relatively young age in SAIs are still unclear.

More than 3.6 million South Asians live in the US, and although this group represents the second fastest growing Asian immigrant population, little is known regarding their increased risk for CAD ([@b74-vhrm-4-0953]). Because the population is scattered across the nation, it has been difficult to fully study the problem and to raise awareness within communities. There has been much speculation about what causes the increased occurrence of and mortality from CAD in SAIs. Not uniform groups, South Asians include ethnic subgroups with different cultures and practices, and the prevalence of recognized risk factors for CAD varies among the subgroups ([@b1-vhrm-4-0953]; [@b10-vhrm-4-0953]; [@b8-vhrm-4-0953]; [@b29-vhrm-4-0953]). As a whole, however, South Asians and SAIs have a much higher prevalence of diabetes, insulin resistance, central obesity, dyslipidemias (lower high-density lipoprotein \[HDL\], increased lipoprotein \[a\], higher triglycerides), increased thrombotic tendency (increased plasminogen activator inhibitor-1 and decreased tissue plasminogen activator levels), decreased levels of physical activity, and lower birth weights, commonly known as "fetal origins hypothesis syndrome" ([@b24-vhrm-4-0953]; [@b1-vhrm-4-0953]; [@b31-vhrm-4-0953]; [@b8-vhrm-4-0953]; [@b29-vhrm-4-0953]; [@b38-vhrm-4-0953]).

The higher CAD risk in South Asians may be related to a higher prevalence of metabolic syndrome which has become increasingly common among SAIs ([@b31-vhrm-4-0953]; [@b24-vhrm-4-0953]; [@b26-vhrm-4-0953]) as compared to other populations ([Figure 1](#f1-vhrm-4-0953){ref-type="fig"}). The syndrome is characterized by increased abdominal obesity, atherogenic dyslipidemias, high blood pressure, insulin resistance, glucose intolerance, prothrombotic state, and proinflammatory state. However, even taking these differences into account, classical risk factors may not fully explain the increased risk for CAD in South Asians ([@b24-vhrm-4-0953]; [@b31-vhrm-4-0953]; [@b26-vhrm-4-0953]; [@b38-vhrm-4-0953]).

The CAD rates in the US, Australia, Canada, France, Japan, and Finland ([@b62-vhrm-4-0953]) have declined to half over the past 30 years. These vast reductions in CAD mortality are generally attributed to nationwide changes in specific risk factors that were identified through epidemiological research and addressed through population-based interventions ([@b50-vhrm-4-0953]; [@b46-vhrm-4-0953]; [@b44-vhrm-4-0953]). Reduction in risk factors explains most of the decline with modest contributions from advances in treatment ([@b68-vhrm-4-0953]; [@b69-vhrm-4-0953]; [@b66-vhrm-4-0953]; [@b18-vhrm-4-0953]; HPS 2002). Ironically, during this time, the CAD rates doubled in SAIs, and the impact of risk factors and genetic susceptibility appears to be greater in this population compared with others, making SAIs a high-risk group ([@b21-vhrm-4-0953]). Migration is an important factor in determining the increased risk of CAD; however, other migrating populations (eg, Afro-Caribbean) do not have an increased risk of CAD compared with the indigenous population ([@b77-vhrm-4-0953]). Thus, other specific factors must apply to SAIs.

Dyslipidemias in South Asians
=============================

Among numerous genetic and lifestyle parameters, dyslipidemias are one of the most prominent risk factors for CAD. Epidemiological studies have identified low-density lipoprotein (LDL) and HDL as independent risk factors that modulate CAD risk ([@b28-vhrm-4-0953]). Though the primary goal is to reduce LDL levels, however HDL cholesterol levels are among the most predictive risk factors for CAD ([@b28-vhrm-4-0953]; [@b73-vhrm-4-0953]). A growing body of experimental evidence suggests that augmenting the levels or function of HDL and its apolipoproteins can have major vascular protective effects ranging from prevention to stabilization and regression, independent of total or non-HDL cholesterol levels ([@b68-vhrm-4-0953]; [@b69-vhrm-4-0953]; [@b66-vhrm-4-0953]; [@b18-vhrm-4-0953]; [@b33-vhrm-4-0953]). Recent clinical trials have stimulated tremendous interest in the structure, function, and therapeutic potentials of HDL. The National Cholesterol Educational Program Adult Treatment Panel III (NCEP ATP III) guidelines clearly define an HDL level of \<40 mg/dl as an independent risk factor for CAD, and low HDL is often present in high-risk patients with CAD ([@b22-vhrm-4-0953]). Although an inverse relationship between HDL and risk of acute myocardial infarction is highly significant, the relationship is far from perfect.

The common pattern of dyslipidemias seen in SAIs relative to other populations is shown in [Table 1](#t1-vhrm-4-0953){ref-type="table"} (Anand et al 2003). SAIs tend to have higher triglyceride levels, lower HDL levels, and higher lipoprotein a (Lpa) levels. However, a few recent studies on SAIs in the US showed that the average HDL level in both men and women was either normal or high ([@b34-vhrm-4-0953]; [@b39-vhrm-4-0953]). Whether this difference in HDL level is due to differences in migration, physical activity, gene-environment interactions, or other unknown factors is not known.

Based on known ethnic differences in risk prediction, the Framingham prediction model accurately predicts the CAD risk among Caucasians and blacks living in the United States. For Americans of Japanese and Hispanic descent and for Native Americans, the Framingham model overestimates CAD risk. For SAIs, the Framingham model underestimates CAD risk by greater than 100% ([@b15-vhrm-4-0953]; [@b9-vhrm-4-0953]; [@b26-vhrm-4-0953]). Total cholesterol and LDL levels are correlated with the extent and severity of CAD in SAIs as in Caucasians, but at any given total cholesterol or LDL level, SAIs have a greater CAD risk than Caucasians ([@b15-vhrm-4-0953]; [@b9-vhrm-4-0953]; [@b26-vhrm-4-0953]). Therefore, SAIs with dyslipidemias should be treated as the same level of importance as if they had a CAD risk equivalent to patients with diabetes or heart disease.

Over the past decade, lowering LDL levels has been the major target in cardiovascular protection strategies and clinical trials have clearly established that reductions in LDL are associated with a 30%--45% reduction in clinical events ([@b68-vhrm-4-0953]; [@b69-vhrm-4-0953]; [@b66-vhrm-4-0953]; [@b18-vhrm-4-0953]; [@b33-vhrm-4-0953]). However, despite low LDL and normal HDL levels, many patients continue to have cardiac events. One can calculate from the published data ([@b13-vhrm-4-0953]) that 44% of the CAD clinical events occurred in men with HDL levels greater than 40 mg/dl and 43% in women with HDL levels greater than 50 mg/dl. Because a significant number of CAD events occur in patients with normal LDL and HDL levels, there has been a continuing search for markers with better predictive value.

HDL role in CAD
===============

Lipoproteins are complexes of proteins, phospholipids, and cholesterol. HDL is the smallest and densest of the lipoproteins because of its high protein content. Proteins make up about 50% of its mass and apolipoprotein A-I (Apo A-I) accounts for 70% of that protein component ([@b28-vhrm-4-0953]).

Apo A-I is a 243 amino acid protein synthesized in the liver (70%) and intestine (30%) and secreted into the serum in a lipid-free state ([@b73-vhrm-4-0953]). Individual Apo A-I molecules associate with other Apo A-I molecules, membrane phospholipids, and cholesterol to form lipid-poor pre-β-HDL. Lipid-poor HDL assumes a double-belt-like structure which becomes spherical with maturation and addition of cholesterol ([@b73-vhrm-4-0953]).

Lipid-poor β-HDL is able to take up cholesterol from artery wall macrophages via the ATP-binding cassette A-1 (ABCA-1) receptor ([@b28-vhrm-4-0953]). Cholesterol is transferred into lipid-poor HDL and is then esterified by the enzyme lecithin-cholesterol acyltransferase. As cholesterol is esterified it is packaged into the core of the HDL leading to formation of the mature spherical lipoprotein.

Mature spherical HDL can then unload its cholesterol by 2 main mechanisms. Transfer of cholesterol back to the liver is facilitated by interaction with the scavenger receptor-B1 (SR-B1) receptor on hepatocytes and leads to formation of bile and secretion into the gut. Alternatively, cholesterol can be transferred from mature HDL to LDL or very-low-density lipoprotein (VLDL), a process dependent on cholesteryl ester transfer protein (CETP). This leads to a recycling of cholesterol, potentially back into the artery wall ([@b28-vhrm-4-0953]; [@b73-vhrm-4-0953]).

HDL has antioxidant, antiinflammatory, and antithrombotic properties that contribute to its function as an antiatherogenic agent. Although our understanding of how HDL protects against CAD is still incomplete, evidence supports at least three major athero-protective mechanisms of HDL. HDL is an integral component of the reverse cholesterol transport process, functioning as a carrier of excess cellular cholesterol from peripheral tissues to the liver, where it is excreted from the body as bile acids and cholesterol. More specifically, HDL mediates efflux of cholesterol from cholesterol-loaded macrophages by passive diffusion, through scavenger receptor B1 (SR B1), and, most significantly, via the protein Apo A-I as mentioned above ([@b78-vhrm-4-0953]; [@b79-vhrm-4-0953]). Apo A-I functions through an ATP-binding cassette transporter A1 (ABCA1) in the vessel wall, where it accepts free cholesterol, forming pre-beta HDL that matures after esterification to cholesteryl esters (CE) and then by lecithin-cholesterol acyltransferase to alpha migrating HDL ([@b71-vhrm-4-0953]; [@b65-vhrm-4-0953]; Mackness et al 2002).A series of antioxidant enzymes which protect LDL from oxidation are associated with HDL. Oxidized lipids are transferred to HDL from LDL and are hydrolyzed by HDL-associated PON1, LCAT, and platelet-activating factor (PAF) acetylhydrolase enzymes ([@b56-vhrm-4-0953]; Mackness et al 2002; Marathe et al 2002). The activities of these enzymes destroy oxidized lipids and also inhibit their formation. Removing the oxidized lipids initiates a positive feedback loop that results in further activation of the enzymes and further destruction of the oxidized lipids. In addition, Apo A-I reduces lipid peroxides within LDL, independent of PON1 (Marathe et al 2002).HDL may protect against CAD by selectively decreasing endothelial cell adhesion molecules, which facilitate the binding of mononuclear cells to the vessel wall and promote lesion development ([@b6-vhrm-4-0953]).

Evidence that HDL may not be protective: dysfunctional HDL
----------------------------------------------------------

According to several recent studies, in patients with CAD, HDL is not only ineffective as an antioxidant but, paradoxically, appears to be pro-oxidant, promoting LDL oxidation and monocytes chemotactic activity in the human artery wall as well as increasing HDL lipid hydroperoxides, as assessed by its lipid peroxide content ([@b57-vhrm-4-0953]; [@b23-vhrm-4-0953]; [@b2-vhrm-4-0953], [@b3-vhrm-4-0953]). In addition, HDL from patients with a history of CAD enhances the oxidation of LDL and of phospholipids in LDL ([@b3-vhrm-4-0953]; [@b54-vhrm-4-0953]). This proinflammatory HDL, which is dysfunctional, accumulates oxidants that inhibit HDL-associated antioxidant enzymes, render Apo A-I unable to promote ABCA1 mediated cholesterol efflux, and promotes the formation of LDL-derived oxidized lipids ([@b23-vhrm-4-0953]) ([Figure 2](#f2-vhrm-4-0953){ref-type="fig"}). The mechanisms underlying this phenomenon are not completely understood. One of the hypothesized mechanisms involves myeloperoxidase ([@b80-vhrm-4-0953]). Apo A-I is targeted by myeloperoxidase, and, when oxidized and nitrated, impairs ABCA1-dependent cholesterol efflux. Furthermore, exposing HDL or Apo A-I to myeloperoxidase almost entirely prevents ABCA1-dependent reverse cholesterol transport ([@b23-vhrm-4-0953]). It has been hypothesized that a certain variant of Apo A-I is susceptible to oxidation and nitration ([@b53-vhrm-4-0953]).

The diagnosis of dysfunctional HDL has historically been made with a cell-based assay that requires endothelial cells, smooth muscle cells, and monocytes. However, the use of a cell-based assay is not practical for large-scale studies. Recently, a cell-free assay was developed to detect HDL that is dysfunctional in preventing the formation or inactivation of oxidized phospholipids ([@b56-vhrm-4-0953]; [@b5-vhrm-4-0953], [@b4-vhrm-4-0953]). This is a rapid test for HDL function that does not require cells and gives results highly comparable to those of the previously described cell-based assay ([@b56-vhrm-4-0953]). Using this assay, investigators determined that HDL from patients with documented CAD was proinflammatory (dysfunctional), while HDL from normal subjects was antiinflammatory. These patients had normal levels of blood lipids, had no major risk factors for CAD, and therefore, would not have been predicted to be at risk for atherosclerosis by conventional risk factor analysis. In short, the new cell-free assay has the potential to allow wide-spread testing for HDL that is dysfunctional and identification of individuals at risk for CAD.

The inflammatory/antiinflammatory properties of HDL can be determined by calculating HDL inflammatory index ([@b56-vhrm-4-0953]; [@b5-vhrm-4-0953], [@b4-vhrm-4-0953]). This index is calculated by normalizing the cell-free assay values obtained for a standard LDL alone to \<1.0. Using this normalization procedure, a test HDL is classified as proinflammatory (dysfunctional) when addition of the test HDL along with an LDL standard to the assay results in a normalized value of 1.0 or greater. Conversely, a value less than 1.0 classifies the test HDL as antiinflammatory. A small study of 20 Caucasian subjects with elevated HDL showed an inflammatory index of 1.28 ± 0.29 in CAD patients compared to 0.35 ± 0.29 in healthy subjects, clearly separating patients from controls ([@b5-vhrm-4-0953]).

Proinflammatory (dysfunctional) HDL in SAIs?
============================================

Current data indicates that a 1% increase in HDL serum concentration can decrease cardiovascular risk by 2%--3%, independent of LDL levels ([@b28-vhrm-4-0953]). However, HDL can have this protective effect only if it is functional. The incidence of prooxidant or proinflammatory HDL (dysfunctional HDL) in SAIs is not known.

A small study done on SAIs showed inflammatory index values of ≥1.00 in 50% (95% CI 0.8772--1.4333) with normal HDL suggesting proinflammatory or dysfunctional HDL ([@b17-vhrm-4-0953]). In addition, proinflammatory HDL (≥1.00) was associated with CAD, using IMT values ≥0.80 mm as surrogate marker for CAD (p = 0.04). The mean HDL inflammatory Index was 0.8772 in the group with CAD and 0.6269 in the group without CAD. Further work is needed to understand the relationship of dysfunctional HDL with HDL levels.

Given that animal and small-scale human studies suggest that measures of the quality and functionality of HDL can provide an improved means of identifying subjects at increased risk for atherosclerotic events, compared with the current practice of only measuring the level of HDL ([@b22-vhrm-4-0953]), the level of dysfunctional HDL and its association with CAD in SAIs needs to be explored in bigger studies. Given the results of small studies, we can hypothesize that SAIs have a high prevalence of dysfunctional HDL and that this could be related to their excessive risk of CAD. We are currently funded by the National Institute of Health ( NIH) to study association of dysfunctional HDL with CAD in SAIs. Similarly, SAIs carry an increased prevalence of metabolic syndrome and diabetes (subclinical chronic inflammation) as compared to other groups, therefore, we predict that this population has increased dysfunctional HDL and is related to coronary events ([@b31-vhrm-4-0953]; [@b72-vhrm-4-0953]; [@b26-vhrm-4-0953]). Patients with metabolic syndrome tend to have dysfunctional HDL (proinflammatory HDL) more often than controls ([@b76-vhrm-4-0953]). Identification of dysfunctional HDL and its association with carotid IMT and metabolic syndrome in SAIs will help to identify high-risk individuals; high risk that cannot be explained by traditional risk factors. Patients found to have dysfunctional HDL and no other CAD risk factors can be targeted for early lipid-lowering treatment which has been shown to improve HDL antiinflammatory function ([@b5-vhrm-4-0953], [@b4-vhrm-4-0953]; [@b45-vhrm-4-0953]). However, weather measures of dysfunctional HDL are superior to other indirect markers like total cholesterol/HDL ratio, Apolipoprotein B/Apo A-I ratio requires more research.

Apo A-I and gene polymorphisms
==============================

Apo A-I (APOAI gene, Apo A-I protein) is the major protein of HDL and consists of a 243 amino acid-long peptide, synthesized mainly in the liver and to some extent in the small intestine. The inverse relationship between HDL plasma levels and CAD has been attributed to the role that HDL and its major constituent Apo A-I play in reverse cholesterol transport (RCT). The efficiency of RCT depends on the specific ability of Apo A-I to promote cellular cholesterol efflux, bind lipids, activate lecithin: cholesterol acyltransferase (LCAT), and form mature HDL that interacts with specific receptors and lipid transfer proteins ([@b70-vhrm-4-0953]; [@b40-vhrm-4-0953]; [@b27-vhrm-4-0953]). The APOAI gene is present along with the APOC3 and APOA4 genes, on chromosome 11(11q23.3-qter). It has also been shown that the A allele of the APOAI gene contributes to the severity of CAD and low levels of HDL among Northern Indians ([@b14-vhrm-4-0953]).

Epidemiological studies have shown that HDL and Apo A-I levels are inversely correlated with the risk of developing CAD ([@b37-vhrm-4-0953]; [@b55-vhrm-4-0953]; [@b14-vhrm-4-0953]). Although various factors such as genetic variations, diet, exercise, alcohol, smoking, hormones, and certain drugs can significantly influence the levels of HDL and Apo A-I ([@b47-vhrm-4-0953]), family and twin studies have demonstrated a strong genetic heritability, accounting for up to 66% of the variability of HDL and Apo A-I levels ([@b12-vhrm-4-0953]; [@b37-vhrm-4-0953]; [@b14-vhrm-4-0953]). Furthermore, 40%--60% of the inter-individual variation in HDL concentrations is controlled at the genetic level ([@b14-vhrm-4-0953]) and the strong positive correlation between plasma levels of Apo A-I and HDL suggests that Apo A-I gene polymorphisms may be linked to variability in HDL levels as well as to dysfunction ([@b14-vhrm-4-0953]; [@b55-vhrm-4-0953]).

More than 40 mutations in Apo A-I have been identified in several ethnic populations ([@b52-vhrm-4-0953]; [@b43-vhrm-4-0953]; [@b12-vhrm-4-0953]; [@b37-vhrm-4-0953]; [@b47-vhrm-4-0953]; [@b14-vhrm-4-0953]), each producing differing HDL activity and levels. Apo A-I gene mutations are separated into three classes. Class I includes mutations that prevent the formation of Apo A-I; class II defects lead to expression of a truncated Apo A-I protein; and class III defects result in an altered functional state of Apo A-I. Not surprisingly, class I mutations are associated with CAD, xanthomatosis, and corneal opacifications, whereas class II mutations exhibit variable phenotypes ([@b52-vhrm-4-0953]; [@b43-vhrm-4-0953]; [@b12-vhrm-4-0953]; [@b27-vhrm-4-0953]; Lusis et al 2000). Mutations affecting the structure of Apo A-I (nonsense mutations with premature stop codons or large genomic deletions) result in an absence of Apo A-I in plasma and a marked reduction in HDL levels ([@b52-vhrm-4-0953]). Interestingly, of the 12 mutations that truncate Apo A-I, not all are associated with CAD. Further, several point mutations have been identified ([@b52-vhrm-4-0953]; [@b43-vhrm-4-0953]; [@b12-vhrm-4-0953]; [@b27-vhrm-4-0953]), and one in particular is associated with low levels of HDL but not with an increased CAD risk and is, instead, associated with a reduction in CAD risk ([@b11-vhrm-4-0953]). This Apo A-I mutation is called Apo A-I milano (Apo A-I~Arg\ 173\ Cys~).

Apo A-I polymorphisms in SAIs
=============================

A majority of the studies on Apo A-I polymorphisms and their association with HDL level and CAD have been carried out in Caucasian and other populations. The association of A*po A-I* gene polymorphisms with carotid IMT as a surrogate marker for atherosclerosis has been examined, but not fully. For example, Apo A-I (L178P) was found to be associated with high IMT measurements (p \< 0.001) in a European population, however due to the small sample size, results can not be generalized ([@b63-vhrm-4-0953]). Similarly, Apo A-I/C-III/A-IV SstI polymorphism was found to be associated with high carotid IMT measurements in a study of a young Finnish population ([@b75-vhrm-4-0953]). However, the role of Apo A-I polymorphisms in individuals with metabolic syndrome and its association with dysfunctional HDL has not yet been fully studied. A few studies have examined Apo A-I polymorphisms in native populations of South Asians from India, however, to our knowledge, no study has examined Apo A-I polymorphisms in SAIs and its association with dysfunctional HDL, IMT, or CAD. Polymorphisms in Apo A-I and other lipid metabolism-related genes have been suggested to be clinically useful in assessing an individual's risk for cardiovascular disease and in conducting genetic-epidemiological evaluations ([@b61-vhrm-4-0953]).

Given that SAIs are significantly under-represented in major clinical trials, evidence-based management strategies for treatment and prevention of CAD specifically in this population is seriously lacking. A literature search for Apo A-I gene mutations in South Asian populations yielded a small study that showed polymorphisms in the Apo lipoprotein C-III promoter gene that were associated with features of metabolic syndrome in South Asian Indians; the relationship of these polymorphisms to CAD was not examined ([@b35-vhrm-4-0953]; [@b32-vhrm-4-0953]; [@b36-vhrm-4-0953]). A recent small study conducted on Pakistanis suggested that the promoter region of the Apo A-I gene may play a role in determining blood pressure ([@b67-vhrm-4-0953]), however, due to insufficient power, these results cannot be generalized. [@b14-vhrm-4-0953] found a correlation between the expression of the Apo A-I G-75A polymorphism in northern Indians, the severity of CAD, and low levels of HDL; however this study was restricted to one ethnic group and relationship was not examined in other ethnic groups. Studies have shown that South Indians carry more CAD risk as compared to North Indians ([@b34-vhrm-4-0953]).

In a small study on SAIs, six novel polymorphisms were identified, one of which, G4 (C938T), was significantly associated with low (\<40 mg/dl) HDL levels (p = 0.03) ([@b16-vhrm-4-0953]). Further research is required to explore Apo A-I polymorphisms in SAIs and correlate possible associations with dysfunctional HDL and CAD. Moreover, it may lead to screening tests that will allow early detection and control of the developing CAD. Also these tests may lead to the development of gene therapy mechanisms useful in the treatment of CAD in SAIs.

Conclusion
==========

People of South Asian origin constitute a large, visible minority in the United States and are known to be at heightened risk for premature CAD. Conventional risk factors clearly confer risk in South Asians but do not adequately explain their excess risk compared with other populations. New risk factors and markers like dysfunctional HDL, genetic polymorphism though shown to be linked with CAD; however greater research is required in South Asians. The rates of CAD have accelerated dramatically amongst South Asians, driven to an important extent by the atherogenic dyslipidemia and type 2 diabetes that have become so common amongst them. South Asians may have a genetic predisposition to CAD; however, environmental, nutritional, and lifestyle factors may also be responsible. South Asians have a much higher prevalence of metabolic syndrome, diabetes, insulin resistance (and resultant hyperinsulinemia), central obesity, dyslipidemias (lower HDL, increased lipoprotein\[a\], higher triglyceride levels), increased thrombotic tendency (increased plasminogen activator inhibitor-1 and decreased tissue plasminogen activator levels), decreased levels of physical activity, and low birth weights ("fetal origins hypothesis"). In addition, the dietary indiscretions and sedentary lifestyle practiced by most South Asians puts them at a higher risk. A multidisciplinary approach involving the population at risk, healthcare personnel, and the government is required to diminish the incidence.

The key to combating the increasing incidence of CAD among South Asians is the treatment of known risk factors through both an individual-based as well as a population-based approach aimed at comprehensive risk factor reduction. In addition, further research is needed to discover new risk factors like dysfunctional HDL that can be responsible for an excess CAD risk, not explained by conventional risk factors.
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###### 

Dyslipidemias in South Asian immigrants relative to other populations ([@b1-vhrm-4-0953])

  Factor                                                             [†](#tfn2-vhrm-4-0953){ref-type="table-fn"}South Asian   [†](#tfn2-vhrm-4-0953){ref-type="table-fn"}European   [†](#tfn2-vhrm-4-0953){ref-type="table-fn"}Chinese   [†](#tfn2-vhrm-4-0953){ref-type="table-fn"}p
  ------------------------------------------------------------------ -------------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------- ----------------------------------------------
  Total cholesterol (mg/dl)                                          211.77 (81.90)                                           184.86 (81.90)                                        183.69 (81.90)                                       0.0001
  LDL (mg/dl)                                                        128.70 (35.10)                                           123.63 (31.20)                                        122.46 (31.20)                                       0.03
  HDL (mg/dl)                                                        38.56 (11.70)                                            46.41 (11.70)                                         46.41 (11.70)                                        0.0001
  Triglycerides (mg/dl)                                              174.44 (115.70)                                          145.96 (115.70)                                       158.42 (115.70)                                      0.005
  Lipoprotein (a) (g/L)[‡](#tfn3-vhrm-4-0953){ref-type="table-fn"}   0.0293 (0.018)                                           0.0259 (0.0119)                                       0.0259 (0.0119)                                      0.001

**Abbreviations:** LDL, low-density lipoprotein; HDL, high-density lipoprotein.

**Notes:**^†^mean (SD)

^‡^Natural Log.
